FATE THERAPEUTICS

Codice
FATE
Risorse esterne
Opinione della community
Prezzo Variazione Volume
4.78 -4.21 €
(-46.83%)
344822
P/E Obiettivo ad 1anno
0 7 €

Compra - Vendi

0
Tutte le tue transazioni per questo titolo

Devi effettuare l'accesso


Grafico

Altri utenti che hanno investito

Transations in last week
Buy: 4
Sell : 2

AngerManagement Genny cash

Commenti


Notizie

A Data-Rich Year Has Analysts Accepting Their Fate Therapeutics Trade - Benzinga

Wedbush reiterated its Outperform rating on Fate Therapeutics Inc (NASDAQ: FATE), saying the company is executing well on advancing its early stage cell therapy pipeline into patients, with significant data catalysts expected later this year. The ... Leggi

Traders Spotlight: Fate Therapeutics, Inc. (NASDAQ:FATE) - Is stories

The stock as of last trading session moved 199.32% up from its 52 week low and was -22.54% behind its 52 week high. The stock's price switched up -0.88% 20-Days Simple Moving Average, added 22.94% from 50-Days Simple Moving Average and rose ...altro » Leggi

Fate Therapeutics Inc (FATE) Trading Down 9.2% on Analyst Downgrade - Chaffey Breeze

Fate Therapeutics logo Shares of Fate Therapeutics Inc (NASDAQ:FATE) fell 9.2% on Tuesday after HC Wainwright lowered their price target on the stock from $8.00 to $6.00. HC Wainwright currently has a buy rating on the stock. Fate Therapeutics traded ... Leggi

Fate Therapeutics Inc (FATE) Trading Down 9.2% Following Analyst ... - The Cerbat Gem

Fate Therapeutics Inc (NASDAQ:FATE) shares fell 9.2% during trading on Tuesday after HC Wainwright lowered their price target on the stock from $8.00 to ... Leggi

Top Institutional Investors That Own Fate Therapeutics, Inc. (FATE ... - Post Analyst

Fate Therapeutics, Inc. (NASDAQ:FATE) reached 215.65% versus a 1-year low price of $1.47. The stock was last seen 5.45% higher, reaching at $4.64 on Mar. Leggi

Analyst Activity – HC Wainwright Lowers Its Price Target On Fate Therapeutics (NASDAQ:FATE) to - Market Exclusive

Fate Therapeutics, Inc. (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company's cell therapy pipeline consists of ... Leggi

The Fate Therapeutics Inc (FATE) Trading 6.7% Higher After Analyst Upgrade - Petro Global News 24

Fate Therapeutics Inc (NASDAQ:FATE) rose 6.7% during mid-day trading on Friday after BMO Capital Markets raised their price target on the stock to $7.00. BMO Capital Markets currently has a buy rating on the stock. Fate Therapeutics traded as high as ... Leggi

Intel, Advanced Micro Devices, Fate Therapeutics News Today - Schaeffers Research (blog)

The stock market is trading higher ahead of this week's rate decision from the Fed. Meanwhile, among specific names in focus are tech stocks Intel Corporation (NASDAQ:INTC) and Advanced Micro Devices, Inc. (NASDAQ:AMD), as well as cancer treatment ...altro » Leggi

A Technical Look At 2 Stocks: Cytokinetics, Incorporated (CYTK ... - Post Analyst

Cytokinetics, Incorporated (NASDAQ:CYTK) last session's volume of 0.36 million shares was higher than its average volume of 0.31 million shares. The stock ...altro » Leggi

Hot Stocks Report: Fate Therapeutics, Inc. (FATE), W.W. Grainger ... - Post Analyst

Fate Therapeutics, Inc. (NASDAQ:FATE) last session's volume of 0.42 million shares was higher than its average volume of 0.37 million shares. The stock, after ...altro » Leggi